


To: **MGM Hospital-Aurangabad**  
N-6, CIDCO  
Aurangabad -  
Contact: 7045919305  
**Report Of: Mrs. MAYURI JADHAV**  
Pt. Contact: 9970918959



Sample ID 2200097486  
Patient ID 1002255693  
Received on 02/08/2022 13:14  
Registered on 03/08/2022 17:50  
Reported on 04/08/2022 11:46  
Referred by **DR.SURESH RAWTE**  
Sonography by **DR.ANUP CHALWADE**

**EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT**

Patient Name: Mrs. MAYURI JADHAV Patient DOB: 04/08/1996  
Ethnicity: Asian City: AURANGABAD Hospital ID: \_\_\_\_\_

**Sample Type:** Serum

**Risk assessment:** Algorithm validated by SURUSS 2003, N.J Wald

**Method:** Time-resolved Fluoroimmunoassay



EVIC Screen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK) guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)

**RISK ASSESSMENT**

Condition	1: 100000	Risk	Visual Scale
T21 (Down syndrome)	1: 100000	Low Risk	LOW INTERMEDIATE HIGH
T18 (Edwards' syndrome)	1: 100000	Low Risk	LOW HIGH
T13 (Patau syndrome)	1: 100000	Low Risk	LOW HIGH
Pre-eclampsia before 34 weeks	1: 3968	Low Risk	LOW HIGH

**MULTIPLE OF MEDIAN (MoM)**

Free β-hCG	0.43	
PAPP-A	0.58	

**INTERPRETATION**

The First Trimester Screening for the given sample is found **SCREEN NEGATIVE**.

**SUGGESTIONS AND OTHER FINDINGS**

In view of low free βhCG, serial growth scans are recommended to assess for fetal growth restriction.



Patient name : Mrs. MAYURI JADHAV

Sample ID : 2200097486

**PREGNANCY DETAILS**

No. of fetuses : 1	EDD : 06/02/2023	Age at Term : 26.5 Years
GA is Based on : CRL 68.1mm at 01/08/2022	LMP Date : 03/05/2022	LMP Certainty : Regular
Smoking : None	Parity : Nulliparous	Height : 162.5 cm
FHR :	Weight : 38.80 Kg	

**Previous pregnancy history**

**Pre-eclampsia history**

**Other findings**

<input type="checkbox"/> Down syndrome	<input type="checkbox"/> Edwards' syndrome	<input type="checkbox"/> PE in previous pregnancy	<input type="checkbox"/> Insulin dependent diabetes
<input type="checkbox"/> Patau syndrome	<input type="checkbox"/> NTD syndrome	<input type="checkbox"/> Pat. mother had PE	<input type="checkbox"/> Chronic hypertension

EDD: Estimated Due Date | GA: Gestation Age | LMP: Last Menstrual Period | FHR: Fetal Heart Rate | NTD: Neural Tube Defect | PE: Pre-eclampsia | DOB: Date of Birth

**SPECIMEN DETAILS**

Sample ID : 2200097486	CRL : 68.1 mm	Test Name	Conc.	Unit	Corr. Mom
Collection Date : 01/08/2022	CRL2 :	Free-β-hCG	17.51	ng/mL	0.43
Scan Date : 01/08/2022	BPD :	NB	Present		
GA at Coll Date : 13 Weeks 0 Days	BPD2 :	NT	1.6	mm	0.96
GA at Scan Date : 13 Weeks 0 Days	HC :	PAPP-A	4062.00	mU/L	0.58
Received on : 02/08/2022	HC2 :	MAP	80.00	mmHg	1.03
		UTPI	1.23	--	0.72

GA: Gestation Age | CRL: Crown Rump Length | BPD: Bi-parietal Diameter | HC: Head Circumference | free-β-hCG: free-Beta Human Chorionic Gonadotropin  
NT: Nuchal Translucency | PAPP-A: Pregnancy-associated Plasma Protein-A

**RISKS**

<b>Disorder: Down Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000	Age risk: 1:1286	
Cutoff 1:250	Risk type Risk At Term	
<b>Disorder: Edwards' Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000	Age risk: 1:11570	
Cutoff 1:100	Risk type Risk At Term	
<b>Disorder: Patau Syndrome</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1:100000	Age risk: 1:34751	
Cutoff 1:100	Risk type Risk At Term	
<b>Disorder: PE &lt;34 weeks</b>	<b>Result:</b>	<b>Low Risk</b> ●
Final risk: 1: 3968		
Cutoff 1: 100	Risk type Risk at Term	

Patient name : Mrs. MAYURI JADHAV

Sample ID : 2200097486

## PRENATAL SCREENING BACKGROUND

Every pregnant woman carries a certain degree of risk that her fetus/baby may have certain chromosomal defect/ abnormalities. Diagnosis of these fetal chromosomal abnormalities requires confirmatory testing through analysis of amniocytes or Chorionic Villous Samples (CVS). However, amniocentesis and CVS procedures carry some degree of risk for miscarriage or other pregnancy complications (Tabor and Alfirevic, 2010). Therefore in routine practice, prenatal screening tests are offered to a pregnant woman to provide her a personalised risk for the most common chromosomal abnormalities (T21-Down syndrome, T18- Edwards' syndrome, T13- Patau syndrome) using her peripheral blood sample. Based on this risk assessment, if the risk is high or intermediate, you can take informed decision of opting for invasive procedure such as amniocentesis or CVS followed by confirmatory diagnostic test(s), as per discussion with your clinician.

### PRENATAL SCREENING TESTS ARE NOT CONFIRMATORY TESTS. THEY ARE LIKELIHOOD ASSESSMENT TESTS.

You may get your prenatal screening result as either of the following:-

#### High Risk

**High Risk or Screen Positive Result:** A High Risk Result does not mean that the pregnancy is affected with the condition. It means that the likelihood of the pregnancy having a condition is higher than the cut-off (Most commonly used cut-off is 1:250 and this represents the risk of pregnancy loss from confirmatory testing through CVS or amniocentesis).

#### Low Risk

**Low Risk or Screen Negative Result:** A Low Risk result does not mean that the pregnancy is not affected with a condition. It means that the likelihood of the pregnancy having a condition is lower than the cut-off.

#### Intermediate Risk

**Intermediate Risk result:** An intermediate Risk result means that the pregnancy has an equivocal or a borderline risk of being affected with a condition. In this case, you may want to choose a second stage screening modality like an Integrated Screening Test that is done between 16 to 20 weeks of pregnancy or a Non-invasive Prenatal Screening Test between 12 to 20 weeks of pregnancy before taking a decision on an invasive confirmatory testing. This will help you improve the sensitivity of the screening test keeping an invasive test a last option were you to come as a high risk in the second stage screening test.

## SIGNIFICANCE OF MULTIPLE OF MEDIANS (MoMs)

Prenatal Screening determines the likelihood of the pregnancy being affected with certain conditions by analysing levels of certain hormones. These hormones are Feto placental products (released by Fetus or placenta). Their levels not only indicate propensity of the fetus being affected with certain chromosomal conditions, they also provide indication of placental insufficiency that can potentially lead to pregnancy complications like Pre-Eclampsia or Intra-Uterine Growth Restriction. It is therefore important to take cognisance of the Reported MoMs alongside the Risk results.

*For more information, visit our website at: [www.lilacinsights.com/faq-pns](http://www.lilacinsights.com/faq-pns)*

## DISCLAIMERS

### Limitations of the Test:

As prenatal screening tests are not confirmatory diagnostic tests, the possibility of false positive or false negative results can not be denied. The results issued for this test does not eliminate the possibility that this pregnancy may be associated with other chromosomal or sub- chromosomal abnormalities, birth defects and other complications.

Nuchal Translucency is the most prominent marker in screening for Trisomy 13, 18, 21 in the first trimester and should be measured in accordance with the Fetal Medicine Foundation (UK) guidelines. Nuchal Translucency or Crown Rump Length measurement, if not performed as per FMF (UK) imaging guidelines may lead to erroneous risk assessments and Lilac Insights bears no responsibility for errors arising due to sonography measurements not performed as per these criteria defined by international bodies such as FMF (UK), ISUOG.

It is assumed that the details provided along with the sample are correct. The manner in which this information is used to guide patient care is the responsibility of the healthcare provider, including advising for the need for genetic counselling or additional diagnostic testing like amniocentesis or Chorionic Villus Sampling. Any diagnostic test should be interpreted in the context of all available clinical findings. As with any medical test, there is always a chance of failure or error in sample analysis though extensive measures are taken to avoid these errors.

### Note:

- Quality of the Down syndrome screening program (Biochemical values, MoMs and Risk assessments) is monitored by UKNEQAS on an ongoing basis.
- This interpretation assumes that patient and specimen details are accurate and correct.
- Lilac Insights does not bear responsibility for ultrasound measurements like CRL,NT,NB etc. We strongly recommend that ultrasound measurements are performed as per FMF (UK)/ISUOG practice guidelines.
- PE risk stratification is done using a cut-off of 1:100 as per ASPRE study.
- It must be clearly understood that the results represent risk and not diagnostic outcomes. Increased risk does not mean that the baby is affected and further tests must be performed before a firm diagnosis can be made. A Low Risk result does not exclude the possibility of Down's syndrome or other abnormalities, as the risk assessment does not detect all affected pregnancies.

END OF REPORT

Page 3 of 3

